MelanomaPhase 1/2NCT02706353
APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
A Phase 1/2 study testing APX005M and Pembrolizumab in people with Melanoma, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
You are being asked to take part in this study because you have metastatic (cancer that has spread) melanoma. The goal of Part 1 of this clinical research study is to find the highest tolerable dose of APX005M that can be given with pembrolizumab that can be given to patients with metastatic melanoma. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Melanoma
- What is being tested?
- APX005M and Pembrolizumab
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 34 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Jun 2017to 10 Mar 2025
- Phase
- Phase 1/2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Be willing and able to provide written informed consent/assent for the trial.
- Histologically or cytologically confirmed malignant melanoma from skin, or mucosal melanoma (i.e. ocular melanoma subjects are not eligible)
- Measurable, unresectable stage III (in transit lesions) or stage IVA, IVB, IVC disease
- At least two injectable lesions (amenable for direct injection or through the use of image guidance such ultrasound [US], CT or MRI) defined as any injectable cutaneous, subcutaneous, nodal, or visceral melanoma lesion ≥ 10 mm in longest diameter
- Age ≥ 18 years
- ECOG performance status 0 or 1
Show all 15Show fewer
- Total bilirubin less than or equal to 2.0 mg/dl, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.
- Platelet count greater than or equal to 100,000/mm^3
- WBC >3000/mm^3
- ANC > 1500/mm^3
- Hemoglobin >9 g/dL
- Serum ALT and AST <3 the upper limit of normal (ULN); <5 ULN if there is liver involvement secondary to the tumor
- Serum creatinine < 2.0 mg/dl
- Seronegative for HIV antibody
- Patients with a negative pregnancy test (urine or serum) must be documented within 14 days of screening for women of childbearing potential (WOCBP). A WOCBP has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 12 consecutive months (i.e. who has not had menses at any time in the preceding 12 consecutive months). Unless surgically sterile by bilateral tubal ligation or vasectomy of partner(s), the patient agrees to continue to use a barrier method of contraception throughout the study and for 4 months after the last dose of APX005M or Pembrolizumab such as: condom, diaphragm, hormonal, IUD, or sponge plus spermicide. Abstinence is an acceptable form of birth control.
Who cannot join
- Patients who have previously received pembrolizumab or PD-/L1 blockade therapy. Adjuvant IFN-a, is allowed if last dose was received at least 6 months of starting study treatment.
- Active autoimmune disease requiring disease-modifying therapy.
- Concurrent systemic steroid therapy higher than physiologic dose (>7.5 mg/day of prednisone or equivalent).
- Any form of active primary or secondary immunodeficiency.
- History of hematologic malignancy.
- Active coagulopathy.
Show all 19Show fewer
- History of New York Heart Association class 3-4 congestive heart failure or history myocardial infarction within 6 months of starting study treatment.
- History of arterial thrombosis within 3 months of starting study treatment.
- Patients with known symptomatic brain metastases requiring systematic corticosteroids. Patients with previous diagnosed brain metastases are eligible if they have completed their treatment and have recovered from acute effects of radiation therapy or surgery prior to the start of study medication, have discontinued corticosteroid treatment for their metastases for at least 2 weeks and are neurologically stable. Mild neurological deficits are allowed, if they do not interfere with the ability to judge the safety profile of APX005M.
- Prior malignancy except the following: adequately treated basal cell or squamous cell skin cancer, in-situ cervical cancer, thyroid cancer (except anaplastic) or any cancer from which the patient has been disease-free for 2 years.
- Subjects who have received prior immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1), anti-CD40.
- Subjects that have received experimental vaccines or other immune therapies should be discussed with the Principal Investigator to confirm eligibility.
- Active known clinically serious infections (> Grade 2 NCI-CTCAE version 4.03).
- Prior systemic therapy, radiation therapy, or surgery within the 28 days of starting study treatment. Palliative radiotherapy to a limited field or palliative cryoablation is allowed after consultation with the Principal Investigator, at any time during the study participation including screening.
- Women of child-bearing potential (WOCBP), women who are pregnant, or women who are nursing.
- Known or underlying medical condition that, in the opinion of the investigator or sponsor, could make the administration of study drug hazardous to the subjects, or could adversely affect the ability of the subject to comply with or tolerate study procedures and/or study therapy, or confound the ability to interpret the tolerability of combined administration of APX005M and Pembrolizumab in treated subjects.
- Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.
- Has received a TB skin test within 14 days before the first dose of study drug.
- Other severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study treatment administration or that may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient an inappropriate candidate for the study.
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
About this study
Official title: Phase I/II Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral CD40 Agonistic Monoclonal Antibody APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
You are being asked to take part in this study because you have metastatic (cancer that has spread) melanoma.
The goal of Part 1 of this clinical research study is to find the highest tolerable dose of APX005M that can be given with pembrolizumab that can be given to patients with metastatic melanoma.
Read more
The goal of Part 2 of this study is to learn if the combination can help to control metastatic melanoma.
The safety of this drug combination will also be studied.
This is an investigational study. APX005M is not FDA approved or commercially available. It is currently being used for research purposes only. Pembrolizumab is FDA approved and commercially available for the treatment of metastatic melanoma. The combination of these drugs to treat metastatic melanoma is investigational.
The study doctor can explain how the study drug is designed to work.
Up to 41 participants will be treated in this study. All will take part at MD Anderson.
Read the detailed description
Study Groups:
If you are found to be eligible to take part in this study, you will be assigned to a study group based on when you join this study. Up to 4 groups of 3 participants will be enrolled in Part 1, and up to 20 participants will be enrolled in Part 2.
If you are enrolled in Part 1, the dose of APX005M you receive will depend on when you join this study. The first group of participants will receive the lowest dose level of APX005M. Each new group will receive a higher dose of APX005M than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of APX005M is found.
If you are enrolled in Part 2, you will receive APX005M at the highest dose that was tolerated in Phase 1
All participants will receive the same dose level of pembrolizumab.
Study Drug Administration:
APX005M will be injected directly into 1 tumor every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses.
The injections may be done with or without the help of a ultrasound, CT, and MRI.
If the doctor thinks it is needed, you may need to stay in the hospital overnight or be monitored by a caregiver for 24 hours after you receive APX005M.
You will receive pembrolizumab by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). The first dose of pembrolizumab will be given 1-2 days before or after your first dose of APX005M.
You will be given a diary to write down any injection site reactions you may have.
Study Visits:
Within 1 week before your first APX005M injection:
- You will have a physical exam.
- You will have a punch biopsy or image-guided biopsy of a tumor to check the status of the disease. To collect a biopsy, the area of skin is numbed with anesthetic and a small cut is made to remove all or part of the affected tissue. To collect a punch biopsy, the area of skin is numbed with anesthetic and a small cut is made to remove all or part of the affected tissue. To perform an image-guided biopsy, a needle is inserted into the affected area using imaging such as CT or ultrasound to collect cells or tissue from an organ, lymph node, or suspected tumor mass. The doctor will use the imaging to guide the needle into the area.
- Blood (about 4½ tablespoons) will be drawn to test your immune system. If you can become pregnant, blood (about 1 teaspoon) may be drawn for a pregnancy test or urine may be collected to test for pregnancy.
- The tumors may be measured and photographed.
On Day 1 of Cycle 1:
- You will have a physical exam.
- Blood (about 5½ tablespoons) will be drawn for routine tests and test your immune system.
- The tumor may be measured and photographed.
On Day 2 of Cycle 1:
- Your vital signs (blood pressure, heart rate, temperature, and breathing rate) will be measured.
- Blood (about 1 teaspoon) will be drawn for routine tests.
- You will have a biopsy of one of the injected tumor sites within about 24 hours after the 1st injection to check the status of the disease.
On Day 3 of Cycle 1:
- Your vital signs will be measured.
- Blood (about 5 tablespoons) will be drawn for routine tests and to test your immune system.
On Days 8 and 15 of Cycle 1:
- Your vital signs will be measured.
- Blood (about 1½ teaspoons) will be drawn for routine tests.
- Blood (about 4½ tablespoons) may be drawn to test your immune system (Day 8 only).
On Day 1 of Cycle 2:
- You will have a physical exam.
- Blood (about 5½ tablespoons) will be drawn for routine tests and to test your immune system.
On Days 8 and 15 of Cycle 2:
- Your vital signs will be measured.
- Blood (about 1½ teaspoons) will be drawn for routine tests.
- Blood (about 4½ tablespoons) may be drawn to test your immune system (Day 8 only).
On Day 1 of Cycle 3 (± 3 days):
- Your vital signs will be measured.
- You will have a physical exam.
- You will have a biopsy of one of the injected tumors and one of the tumors for which you did not have an injection to check the status of the disease.
- The tumors may be measured and photographed.
- You will have CT, MRI/CT, and/or an ultrasound to check the status of the disease.
- Blood (about 2½ teaspoons) will be drawn for routine tests. If you can become pregnant, a pregnancy test may be performed. Urine may be collected for the pregnancy test.
- Blood (about 4½ tablespoons) will be drawn to test your immune system.
On Day 1 of Cycle 4:
- Your vital signs will be measured
- You will have a physical exam.
- Blood (about 2½ teaspoons) will be drawn for routine tests
- Blood (about 4½ tablespoons) will be drawn to test your immune system.
On Day 1 of Cycles 5-8:
- Your vital signs will be measured.
- You will have a physical exam.
- Blood (about 1½ teaspoons) will be drawn for routine tests.
On Day 1 of Cycles 5 and 8 ONLY (± 3 days):
- Blood (about 1½ teaspoons) will be drawn for routine tests.
- Blood (about 4½ tablespoons) will be drawn to test your immune system.
- You may have a biopsy of one of the injected tumors and one of the tumors for which you did not have an injection to check the status of the disease (Cycle 5 only).
- The tumors may be measured and photographed.
- You will have CT, MRI/CT, and/or an ultrasound to check the status of the disease.
Cycles beyond Cycle 8:
°You will have CT, MRI/CT, and/or an ultrasound to check the status of the disease (every 3 months for up to 2 years).
Length of Treatment:
You will be on study for up to 2 years. You will be taken off study if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions.
If your doctor thinks it is in your benefit, you may continue to receive pembrolizumab as standard of care after you are off this study. Your doctor will describe this in more detail.
Off-Study Visit:
If you have to go off study early because the disease got worse or you had intolerable side effects:
- Your vital signs will be measured.
- You will have a physical exam.
- Blood (about 1½ teaspoons) will be drawn for routine tests.
- Blood (about 4½ tablespoons) will be drawn to test your immune system.
Follow-Up:
Within 2 weeks after your last study drug dose and every 8-12 weeks after that, you may have scans to check the status of the disease. Your doctor will decide what type of scans you will have.
If you choose to seek care at another hospital, the study staff will call you every 3 months for up to 2 years after your last study drug dose. You will be asked how you are doing. The calls should last about 5 minutes.
- Conditions
- Melanoma
- Being tested
- APX005M, Pembrolizumab
- Keywords
- Melanoma, Metastatic Melanoma, Intratumoral APX005M, Pembrolizumab, Keytruda, MK-3475, SCH-900475
- Medical subject headings
- Melanoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
APX005MDrug
Dose Escalation Phase Starting Dose Level of APX005M: 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses.
Dose Expansion Phase Starting Dose Level of APX005M: Maximum tolerated dose from Dose Escalation Phase.
PembrolizumabDrug
Also called Keytruda, MK-3475, SCH-900475
Dose Escalation and Expansion Phase Dose of Pembrolizumab: 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.
| Study group | Role | What they receive |
|---|---|---|
| APX005M + Pembrolizumab | Experimental | Dose Escalation Phase:
Starting dose level of APX005M is 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses. Tumor site chosen based on volume to be injected.
All participants receive Pembrolizumab at 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.
Dose Expansion Phase:
Starting dose level of APX005M is maximum tolerated dose from Dose Escalation Phase.
Participants receive same dosage of Pembrolizumab as in Dose Escalation Phase. Receives: Drug: APX005M; Drug: Pembrolizumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and Tolerability
To assess safety and tolerability of intratumoral APX005M given with systemic pembrolizumab and identify of the maximum tolerated dose/recommended phase 2 dose (MTD/PR2D) of the combination therapy in patients with metastatic melanoma.
Measured: Baseline to 2 years
Overall Response Rate (ORR)
To assess best overall response after ibtratumoral injection of APX005M in combination with systemic pembrolizumab
Measured: Baseline to 2 years
Secondary outcomes (3)
Evaluation of Intratumoral CD8⁺ T Cells
To comprehensively assess CD8⁺ T cell responses in injected tumors, we employed multiplex immunofluorescence (mIF).
Measured: Baseline to week 6
Overall Safety and Tolerability
To assess the overall safety and tolerability of IT APX005M given with systemic pembrolizumab in patients with metastatic melanoma.
Measured: Baseline to 2 years
Anti-tumor Immune Responses and Clinical Efficacy
To evaluate anti-tumor immune responses and clinical efficacy of intratumoral injection of IT APX005M with systemic Pembrolizumab
Measured: Baseline to 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Mar 2016 (estimated)
- Study start2 Jun 2017
- Primary completion10 Mar 2025
- Study completion10 Mar 2025
Why it stopped: \<75% participant accrual
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for MelanomaStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- Apexigen America, Inc., Pyxis Oncology
- Responsible party
- Sponsor
- Investigators
- Adi Diab, MD, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02706353
- Sponsor's protocol ID
- 2015-0654
- Other IDs
- NCI-2016-00675
- Status last verified
- Nov 2025
- First submitted
- 8 Mar 2016
- Last updated
- 21 Nov 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase I/II Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral CD40 Agonistic Monoclonal Antibody APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
- ClinicalTrials.gov ID
- NCT02706353
- Acronym / sponsor ID
- 2015-0654
- Conditions
- Melanoma
- Keywords
- Melanoma, Metastatic Melanoma, Intratumoral APX005M, Pembrolizumab, Keytruda, MK-3475, SCH-900475
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: \<75% participant accrual
- Enrolment
- 34 participants (actual)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Collaborators
- Apexigen America, Inc., Pyxis Oncology
- Study start
- 2 Jun 2017 (actual)
- Primary completion
- 10 Mar 2025 (actual)
- Study completion
- 10 Mar 2025 (actual)
- First posted
- 11 Mar 2016 (estimated)
- Results
- Posted 21 Nov 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
You are being asked to take part in this study because you have metastatic (cancer that has spread) melanoma.
The goal of Part 1 of this clinical research study is to find the highest tolerable dose of APX005M that can be given with pembrolizumab that can be given to patients with metastatic melanoma.
The goal of Part 2 of this study is to learn if the combination can help to control metastatic melanoma.
The safety of this drug combination will also be studied.
This is an investigational study. APX005M is not FDA approved or commercially available. It is currently being used for research purposes only. Pembrolizumab is FDA approved and commercially available for the treatment of metastatic melanoma. The combination of these drugs to treat metastatic melanoma is investigational.
The study doctor can explain how the study drug is designed to work.
Up to 41 participants will be treated in this study. All will take part at MD Anderson.
Detailed description
Study Groups:
If you are found to be eligible to take part in this study, you will be assigned to a study group based on when you join this study. Up to 4 groups of 3 participants will be enrolled in Part 1, and up to 20 participants will be enrolled in Part 2.
If you are enrolled in Part 1, the dose of APX005M you receive will depend on when you join this study. The first group of participants will receive the lowest dose level of APX005M. Each new group will receive a higher dose of APX005M than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of APX005M is found.
If you are enrolled in Part 2, you will receive APX005M at the highest dose that was tolerated in Phase 1
All participants will receive the same dose level of pembrolizumab.
Study Drug Administration:
APX005M will be injected directly into 1 tumor every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses.
The injections may be done with or without the help of a ultrasound, CT, and MRI.
If the doctor thinks it is needed, you may need to stay in the hospital overnight or be monitored by a caregiver for 24 hours after you receive APX005M.
You will receive pembrolizumab by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). The first dose of pembrolizumab will be given 1-2 days before or after your first dose of APX005M.
You will be given a diary to write down any injection site reactions you may have.
Study Visits:
Within 1 week before your first APX005M injection:
- You will have a physical exam.
- You will have a punch biopsy or image-guided biopsy of a tumor to check the status of the disease. To collect a biopsy, the area of skin is numbed with anesthetic and a small cut is made to remove all or part of the affected tissue. To collect a punch biopsy, the area of skin is numbed with anesthetic and a small cut is made to remove all or part of the affected tissue. To perform an image-guided biopsy, a needle is inserted into the affected area using imaging such as CT or ultrasound to collect cells or tissue from an organ, lymph node, or suspected tumor mass. The doctor will use the imaging to guide the needle into the area.
- Blood (about 4½ tablespoons) will be drawn to test your immune system. If you can become pregnant, blood (about 1 teaspoon) may be drawn for a pregnancy test or urine may be collected to test for pregnancy.
- The tumors may be measured and photographed.
On Day 1 of Cycle 1:
- You will have a physical exam.
- Blood (about 5½ tablespoons) will be drawn for routine tests and test your immune system.
- The tumor may be measured and photographed.
On Day 2 of Cycle 1:
- Your vital signs (blood pressure, heart rate, temperature, and breathing rate) will be measured.
- Blood (about 1 teaspoon) will be drawn for routine tests.
- You will have a biopsy of one of the injected tumor sites within about 24 hours after the 1st injection to check the status of the disease.
On Day 3 of Cycle 1:
- Your vital signs will be measured.
- Blood (about 5 tablespoons) will be drawn for routine tests and to test your immune system.
On Days 8 and 15 of Cycle 1:
- Your vital signs will be measured.
- Blood (about 1½ teaspoons) will be drawn for routine tests.
- Blood (about 4½ tablespoons) may be drawn to test your immune system (Day 8 only).
On Day 1 of Cycle 2:
- You will have a physical exam.
- Blood (about 5½ tablespoons) will be drawn for routine tests and to test your immune system.
On Days 8 and 15 of Cycle 2:
- Your vital signs will be measured.
- Blood (about 1½ teaspoons) will be drawn for routine tests.
- Blood (about 4½ tablespoons) may be drawn to test your immune system (Day 8 only).
On Day 1 of Cycle 3 (± 3 days):
- Your vital signs will be measured.
- You will have a physical exam.
- You will have a biopsy of one of the injected tumors and one of the tumors for which you did not have an injection to check the status of the disease.
- The tumors may be measured and photographed.
- You will have CT, MRI/CT, and/or an ultrasound to check the status of the disease.
- Blood (about 2½ teaspoons) will be drawn for routine tests. If you can become pregnant, a pregnancy test may be performed. Urine may be collected for the pregnancy test.
- Blood (about 4½ tablespoons) will be drawn to test your immune system.
On Day 1 of Cycle 4:
- Your vital signs will be measured
- You will have a physical exam.
- Blood (about 2½ teaspoons) will be drawn for routine tests
- Blood (about 4½ tablespoons) will be drawn to test your immune system.
On Day 1 of Cycles 5-8:
- Your vital signs will be measured.
- You will have a physical exam.
- Blood (about 1½ teaspoons) will be drawn for routine tests.
On Day 1 of Cycles 5 and 8 ONLY (± 3 days):
- Blood (about 1½ teaspoons) will be drawn for routine tests.
- Blood (about 4½ tablespoons) will be drawn to test your immune system.
- You may have a biopsy of one of the injected tumors and one of the tumors for which you did not have an injection to check the status of the disease (Cycle 5 only).
- The tumors may be measured and photographed.
- You will have CT, MRI/CT, and/or an ultrasound to check the status of the disease.
Cycles beyond Cycle 8:
°You will have CT, MRI/CT, and/or an ultrasound to check the status of the disease (every 3 months for up to 2 years).
Length of Treatment:
You will be on study for up to 2 years. You will be taken off study if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions.
If your doctor thinks it is in your benefit, you may continue to receive pembrolizumab as standard of care after you are off this study. Your doctor will describe this in more detail.
Off-Study Visit:
If you have to go off study early because the disease got worse or you had intolerable side effects:
- Your vital signs will be measured.
- You will have a physical exam.
- Blood (about 1½ teaspoons) will be drawn for routine tests.
- Blood (about 4½ tablespoons) will be drawn to test your immune system.
Follow-Up:
Within 2 weeks after your last study drug dose and every 8-12 weeks after that, you may have scans to check the status of the disease. Your doctor will decide what type of scans you will have.
If you choose to seek care at another hospital, the study staff will call you every 3 months for up to 2 years after your last study drug dose. You will be asked how you are doing. The calls should last about 5 minutes.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| APX005M + Pembrolizumab | Experimental | Drug: APX005M, Drug: PembrolizumabDose Escalation Phase: Starting dose level of APX005M is 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses. Tumor site chosen based on volume to be injected. All participants receive Pembrolizumab at 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M. Dose Expansion Phase: Starting dose level of APX005M is maximum tolerated dose from Dose Escalation Phase. Participants receive same dosage of Pembrolizumab as in Dose Escalation Phase. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (15 listed)
- Be willing and able to provide written informed consent/assent for the trial.
- Histologically or cytologically confirmed malignant melanoma from skin, or mucosal melanoma (i.e. ocular melanoma subjects are not eligible)
- Measurable, unresectable stage III (in transit lesions) or stage IVA, IVB, IVC disease
- At least two injectable lesions (amenable for direct injection or through the use of image guidance such ultrasound [US], CT or MRI) defined as any injectable cutaneous, subcutaneous, nodal, or visceral melanoma lesion ≥ 10 mm in longest diameter
- Age ≥ 18 years
Key exclusion criteria (19 listed)
- Patients who have previously received pembrolizumab or PD-/L1 blockade therapy. Adjuvant IFN-a, is allowed if last dose was received at least 6 months of starting study treatment.
- Active autoimmune disease requiring disease-modifying therapy.
- Concurrent systemic steroid therapy higher than physiologic dose (>7.5 mg/day of prednisone or equivalent).
- Any form of active primary or secondary immunodeficiency.
- History of hematologic malignancy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| APX005MDose Escalation Phase Starting Dose Level of APX005M: 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses. Dose Expansion Phase Starting Dose Level of APX005M: Maximum tolerated dose from Dose Escalation Phase. | Drug | APX005M + Pembrolizumab |
| PembrolizumabAlso: Keytruda, MK-3475, SCH-900475Dose Escalation and Expansion Phase Dose of Pembrolizumab: 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M. | Drug | APX005M + Pembrolizumab |
Primary outcome
Safety and Tolerability
Time frame: Baseline to 2 years
To assess safety and tolerability of intratumoral APX005M given with systemic pembrolizumab and identify of the maximum tolerated dose/recommended phase 2 dose (MTD/PR2D) of the combination therapy in patients with metastatic melanoma.
Overall Response Rate (ORR)
Time frame: Baseline to 2 years
To assess best overall response after ibtratumoral injection of APX005M in combination with systemic pembrolizumab
3 secondary outcomes
Evaluation of Intratumoral CD8⁺ T Cells
Time frame: Baseline to week 6
Overall Safety and Tolerability
Time frame: Baseline to 2 years
Anti-tumor Immune Responses and Clinical Efficacy
Time frame: Baseline to 2 years
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- University of Texas MD Anderson Cancer Center WebsiteLink provided by the sponsor.
Related trials for Melanoma
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1
IL-17 Blockade to Decrease irAEs (REPLAY)
Metastatic Melanoma
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 1
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
Melanoma
Active, not recruitingPhase 1/2
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
Melanoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Adi Diab, MD principal investigator
M.D. Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing APX005M and Pembrolizumab in people with Melanoma, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 21 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 21 Nov 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety and Tolerability (time frame: Baseline to 2 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2025.